Eliem Therapeutics Inc ELYM shares are trading higher after the company completed a review of its business, including the status of its programs, resources, and capabilities.
The company has decided to halt further development of its Kv7 program and to conduct a comprehensive exploration of strategic alternatives.
Earlier this year, Eliem Therapeutics announced reprioritizing its pipeline to focus on its high-potential preclinical Kv7.2/3 program (Kv7 Program) and the development of its lead Kv7.2/3 candidate, ETX-123.
The company paused all further development of ETX-155, a GABAA receptor positive allosteric modulator neuroactive steroid (GABAA PAM) phase 2-ready for major depressive disorder (MDD), with the potential to also pursue development in epilepsy.
Eliem has engaged Leerink Partners to act as a strategic advisor.
As of June 30, 2023, the company had a preliminary unaudited amount of approximately $102.6 million in cash, cash equivalents, and investments in marketable securities.
Price Action: ELYM shares are up 5.36% at $2.95 on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
